March 2025 in “International Journal of Trichology” Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
5 citations
,
July 2019 in “Photodiagnosis and photodynamic therapy” Using tacalcitol ointment with photodynamic therapy may effectively treat follicular mucinosis with scalp hair loss.
July 2024 in “Russian Journal of Child Neurology” Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
33 citations
,
December 2023 in “Cell Death Discovery” Cepharanthine may help treat gastric cancer by causing cancer cell death and affecting energy use.
September 2025 in “Bioengineering” The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
October 2022 in “Journal of Armed Forces Medical College, Bangladesh” Tofacitinib is effective and safe for treating alopecia areata.
April 2016 in “Journal of Investigative Dermatology” Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
4 citations
,
May 2023 in “Research Square (Research Square)” Cepharanthine can potentially treat gastric cancer by stopping tumor growth.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
58 citations
,
November 2000 in “Journal of the American Veterinary Medical Association” Lufenuron effectively and quickly treats fungal infections in dogs and cats without side effects.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
April 2024 in “Journal of pharmacy & pharmacognosy research” A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
September 2024 in “Cermin Dunia Kedokteran” Improving medical training is key to eradicating frambusia by 2030.
1 citations
,
August 2025 in “Journal of Neonatal Surgery” The nanogel with Ciclopirox Olamine is a promising treatment for skin yeast infections.
January 2026 in “PubMed Central” Clobetasol is more effective than metformin for treating localized alopecia areata.
12 citations
,
May 2023 in “Molecules” Polygoni Cuspidati Rhizoma et Radix contains compounds that inhibit certain enzymes.
Long-term use of seizure medications can disrupt calcium metabolism, but this can be treated with vitamin D or UV light and does not affect seizure control.
47 citations
,
December 2011 in “Experimental Dermatology” CGRP may help protect hair follicles from immune system attacks, potentially slowing hair loss.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
January 2003 in “Journal of Clinical Dermatology” Cyclosporin promotes hair growth by boosting cell growth and reducing cell death.
August 2025 in “Annals of Medicine” Mycophenolate mofetil may safely help restore skin color in depigmentation conditions.
May 2026 in “SKIN The Journal of Cutaneous Medicine” Baricitinib may cause low blood sugar in some patients, so careful monitoring is needed.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.